Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Benzinga

2026.10.16 10:22 (GMT+0)

Abrir em Benzinga